We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $31.29, demonstrating a +2.93% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.09%.
The stock of company has risen by 5.01% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.86 per share and revenue of $25 million, which would represent changes of -84.16% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $31.29, demonstrating a +2.93% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.09%.
The stock of company has risen by 5.01% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.86 per share and revenue of $25 million, which would represent changes of -84.16% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.